WO2022026622A3 - Treatment of viral diseases - Google Patents

Treatment of viral diseases Download PDF

Info

Publication number
WO2022026622A3
WO2022026622A3 PCT/US2021/043569 US2021043569W WO2022026622A3 WO 2022026622 A3 WO2022026622 A3 WO 2022026622A3 US 2021043569 W US2021043569 W US 2021043569W WO 2022026622 A3 WO2022026622 A3 WO 2022026622A3
Authority
WO
WIPO (PCT)
Prior art keywords
viral diseases
treatment
naltrexol
naltrexone
naloxone
Prior art date
Application number
PCT/US2021/043569
Other languages
French (fr)
Other versions
WO2022026622A2 (en
Inventor
Noreen GRIFFIN
Fengping Shan
Michael K HANDLEY
Original Assignee
Cytocom Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytocom Inc. filed Critical Cytocom Inc.
Priority to EP21848742.9A priority Critical patent/EP4188546A2/en
Publication of WO2022026622A2 publication Critical patent/WO2022026622A2/en
Publication of WO2022026622A3 publication Critical patent/WO2022026622A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to methods of preventing or treating in patients suffering from viral diseases such as Influenza A and novel coronavirus 2019 (COVID-19) comprising administering to a patient in need thereof a therapeutically effective amount of methionine enkephalin (MENK) alone or in combination with (+) 6B naltrexol, (-) 6B naltrexol, (+) naltrexone, (-) naltrexone, (+) naloxone and (-) naloxone or a pharmaceutically acceptable salt thereof.
PCT/US2021/043569 2020-07-28 2021-07-28 Treatment of viral diseases WO2022026622A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP21848742.9A EP4188546A2 (en) 2020-07-28 2021-07-28 Treatment of viral diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063057641P 2020-07-28 2020-07-28
US63/057,641 2020-07-28

Publications (2)

Publication Number Publication Date
WO2022026622A2 WO2022026622A2 (en) 2022-02-03
WO2022026622A3 true WO2022026622A3 (en) 2022-03-31

Family

ID=80036066

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2021/043569 WO2022026622A2 (en) 2020-07-28 2021-07-28 Treatment of viral diseases

Country Status (2)

Country Link
EP (1) EP4188546A2 (en)
WO (1) WO2022026622A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11878036B2 (en) * 2022-05-25 2024-01-23 Neuvian LLC Vaginal care compositions and methods of improving vaginal health
CN114931580B (en) * 2022-05-26 2024-04-19 军事科学院军事医学研究院军事兽医研究所 Application of itravirin in anti-rabies virus and screening method of anti-rabies virus drugs

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110245278A1 (en) * 2010-03-31 2011-10-06 Mustafa Nevzat Ilac Sanayii A.S. Compositions of opioid antagonists and methods for treating conditions caused by the varicella-zoster virus therewith
WO2012138911A2 (en) * 2011-04-05 2012-10-11 The Administrators Of The Tulane Educational Fund Conjugates of anti-hiv drugs and somatostatin analogs

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110245278A1 (en) * 2010-03-31 2011-10-06 Mustafa Nevzat Ilac Sanayii A.S. Compositions of opioid antagonists and methods for treating conditions caused by the varicella-zoster virus therewith
WO2012138911A2 (en) * 2011-04-05 2012-10-11 The Administrators Of The Tulane Educational Fund Conjugates of anti-hiv drugs and somatostatin analogs

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BREYER-PFAFF U, NILL K: "Carbonyl reduction of naltrexone and dolasetron by oxidoreductases isolated from human liver cytosol", JOURNAL OF PHARMACY AND PHARMACOLOGY : JPP, JOHN WILEY & SONS LTD, LONDON, GB, vol. 56, no. 12, 18 February 2010 (2010-02-18), GB , pages 1601 - 1606, XP055921259, ISSN: 0022-3573, DOI: 10.1211/0022357045020 *
DONG ET AL.: "Discovering drugs to treat coronavirus disease 2019 (COVID-19", DRUG DISCOVERIES & THERAPEUTICS, vol. 14, no. 1, 2020, pages 58 - 60, XP055678985, [retrieved on 20200229], DOI: 10.5582/ddt.2020.01012 *

Also Published As

Publication number Publication date
EP4188546A2 (en) 2023-06-07
WO2022026622A2 (en) 2022-02-03

Similar Documents

Publication Publication Date Title
IL189546A0 (en) Therapy for the treatment of disease
WO2022026622A3 (en) Treatment of viral diseases
WO2006017188A3 (en) Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients
WO2006029036A3 (en) Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis
WO2006108424A3 (en) Beta-2 adrenoceptor agonists for treating connective tissue diseases of the skin
NZ613291A (en) Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
WO2005058233A3 (en) Methods for treatment of acute pancreatitis
JP2009500045A5 (en)
RU2004135563A (en) MEDICINE FOR TREATING AN INCREASED ACTIVITY OF THE BLADDER
NZ605469A (en) Nalbuphine-based formulations and uses thereof
CA2632207C (en) Use of calcitonin for the treatment of ra
EA200601579A1 (en) PEPTIDE, IMPROVING THE RESISTANCE OF CAPILLARIES, PHARMACEUTICAL COMPOSITION ON ITS BASIS AND METHOD OF ITS APPLICATION
WO2009003694A3 (en) Method for treating diseases related to mitochondrial dysfunction
EA200700178A1 (en) PEPTIDE, HAVING STRESS-PROTECTIVE ACTION, PHARMACEUTICAL COMPOSITION ON ITS BASIS AND ITS APPLICATION
CA2519789A1 (en) Aplidine for multiple myeloma treatment
MX2021008986A (en) Methods of treating a patient having parkinson's disease.
WO2008088987B1 (en) Treatment of pain with naloxone
SE0102887D0 (en) New formulation
EE200200549A (en) Split dose therapy with vascular damaging activity
CA2469702A1 (en) Darifenacin for use in the treatment of urgency induced by overactive bladder
WO2021202992A3 (en) Rapid point of care assay for the detection of the asymptomatic carrier state of covid-19
EA202193190A1 (en) COMPOSITION INCLUDING PRIDOPIDINE AND ITS ANALOGUE FOR THE TREATMENT OF HUNTINGTON'S DISEASE AND ITS SYMPTOMS
AU2003294834A1 (en) Anthranilic acid amide derivatives and their pharmaceutical use
RU2012114097A (en) THERAPEUTIC AGENT AGAINST CHRONIC PAIN
RU2005131943A (en) MEDICINAL AND / OR PREVENTIVE MEANS FOR CHRONIC SKIN DISEASES

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21848742

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2021848742

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2021848742

Country of ref document: EP

Effective date: 20230228

NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21848742

Country of ref document: EP

Kind code of ref document: A2